spacer
home > white papers > Is Your Biobank Ready for the Challenge of Biomarker-based Research? - BioFortis
WHITE PAPERS

BioFortis

phone +1.443.276.2464
email info@biofortis.com
web http://www.biofortis.com
email 10320 Little Patuxent Pkwy, Suite 410, Columbia, MD 21044

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
Is Your Biobank Ready for the Challenge of Biomarker-based Research?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Wickham Laboratories to present at Cleanroom Technology Conference 2018

We are pleased to announce our CEO, Dr John McKenzie, will be presenting on ‘Microbiological Considerations in Cleanroom Validation’ at the Cleanroom Technology Conference to be held 16th-17th May, 2018.
More info >>


White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>


Industry Events

Outsourcing in Clinical Trials Medical Device USA 2018

11-12 July 2018, Minneapolis, Minnesota

6th Outsourcing in Clinical Trials conference is the only clinical outsourcing platform for medical device companies within Medical Alley this year.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement